Argenx SE
(NASDAQ: ARGX)
Balfour Capital Group has issued a buy recommendation
for Argenx SE (ARGX) on November 3rd, 2025
Argenx SE is a commercial-stage immunology biotechnology company pioneering the use of FcRn antibody recycling and related immunomodulatory mechanisms to treat severe autoimmune diseases. Headquartered in Ghent, Belgium, argenx employs approximately 1,300 staff globally, with major operational hubs in the Netherlands, the United States, and Japan. Its lead therapy VYVGART® (efgartigimod) is approved in multiple geographies for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), including the subcutaneous Hytrulo formulation and a prefilled syringe designed for at-home administration. The company’s expanding pipeline includes FcRn-targeted candidates, complement inhibitors, and co-stimulatory pathway antibodies addressing additional autoimmune conditions in neurology, hematology, and nephrology.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $826.28 on November 3rd, 2025.
- Our designated price target stands at $1200.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
2025 Q3 EARNING REPORT
A Q3 report evaluates company financials for investors.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
Balfour Capital Group wants to clarify that our recommendation to Buy Argenx SE (EBR: ARGX)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
